Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR | Leukemia
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Carfilzomib in multiple myeloma
KYPROLIS-carfilzomib - Biotech Due Diligence
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Amgen presents new data for Kyprolis in multiple myeloma at EHA
Cancers | Free Full-Text | Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
Second Phase 3 Study Shows KYPROLIS Regimen Improves Overall Survival in Patients with Relapsed MM | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma - YouTube
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma ( ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
Clinical Challenges in Patients With Relapsed/Refractory Multiple Myeloma (Transcript)
PDF) Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study
PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III
Phase 3 Studies Show Kyprolis (Carfilzomib) Extends Progression Free Survival for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
